Rob Dillard

DocwireNews

Researchers used the HER2DX ERBB2 mRNA score to predict treatment responses and long-term prognosis in first-line metastatic HER2-positive (HER+) breast cancer (BC) patients treated with a taxane-trastuzumab-pertuzumab combination (THP). The findings are being presented at ESMO Breast Cancer 2024, taking place May 15-17 in Berlin, Germany.This study assessed 85 patients with advanced HER2+ BC treated with the standard THP regimen between 2010 and 2024. Researchers correlated HER2DX ERBB2 mRNA scores, both as a continuous variable and as predefined categories (low, medium, high), with progression-free survival (PFS) and overall survival (OS) using Cox regression models.According to the findings, the HER2DX ERBB2 score was significantly associated with both PFS and OS, especially in the ERRB2-high group, in which researchers observed better PFS (28.6 vs 12.5 months; hazard ratio [HR], 0.45; 95% CI, 0.26-0.78; P=.005) and OS (not reached vs 29.8 months; HR, 0.23; 95% CI, 0.12-0.44; P&lt;.001).&ldquo;The HER2DX ERBB2 mRNA score shows a significant association with improved survival in metastatic HER2+ BC patients treated initially with THP. Additional validation of the HER2DX ERBB2 score and integration of prognostic clinical factors might refine and optimize treatment strategies in this clinical setting,&rdquo; the researchers concluded.

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

HER2DX ERBB2 mRNA Score Linked to Improved Survival in First-line Metastatic HER2-Positive Breast Cancer

HER2 Breast Cancer

A recent study found that the HER2DX ERBB2 mRNA score was significantly associated with improved survival in patients with metastatic HER2-positive breast cancer.

HER2DX ERBB2 mRNA Score Linked to Improved Survival in First-line Metastatic HER2+ Breast Cancer

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe